Stifel Financial Corp decreased its holdings in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 46.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 337,158 shares of the company's stock after selling 287,718 shares during the quarter. Stifel Financial Corp owned 0.41% of Editas Medicine worth $428,000 at the end of the most recent reporting period.
Other large investors also recently added to or reduced their stakes in the company. Ieq Capital LLC purchased a new position in Editas Medicine in the 4th quarter worth approximately $31,000. Thrive Wealth Management LLC purchased a new stake in Editas Medicine in the 4th quarter worth about $36,000. Intech Investment Management LLC boosted its holdings in Editas Medicine by 43.1% during the 4th quarter. Intech Investment Management LLC now owns 40,942 shares of the company's stock valued at $52,000 after acquiring an additional 12,336 shares during the period. Virtu Financial LLC purchased a new position in shares of Editas Medicine during the fourth quarter worth approximately $90,000. Finally, SG Americas Securities LLC lifted its holdings in shares of Editas Medicine by 103.7% in the 4th quarter. SG Americas Securities LLC now owns 81,669 shares of the company's stock worth $104,000 after buying an additional 41,573 shares during the period. 71.90% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several equities analysts recently issued reports on the stock. Robert W. Baird cut their price objective on shares of Editas Medicine from $8.00 to $4.00 and set an "outperform" rating on the stock in a report on Tuesday. Cantor Fitzgerald upgraded shares of Editas Medicine from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 29th. HC Wainwright started coverage on shares of Editas Medicine in a report on Monday, April 28th. They issued a "buy" rating and a $3.00 price target on the stock. Finally, StockNews.com raised Editas Medicine from a "sell" rating to a "hold" rating in a report on Wednesday. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating, two have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Editas Medicine presently has a consensus rating of "Hold" and a consensus target price of $5.36.
View Our Latest Research Report on EDIT
Editas Medicine Price Performance
Shares of NASDAQ EDIT traded up $0.12 during midday trading on Friday, hitting $1.51. 1,603,717 shares of the company's stock were exchanged, compared to its average volume of 2,570,966. The firm's fifty day simple moving average is $1.35 and its 200-day simple moving average is $1.67. The company has a market cap of $126.40 million, a PE ratio of -0.59 and a beta of 2.15. Editas Medicine, Inc. has a twelve month low of $0.91 and a twelve month high of $6.22.
Editas Medicine (NASDAQ:EDIT - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.51) by $0.08. Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%. The company had revenue of $4.66 million for the quarter, compared to analyst estimates of $0.79 million. During the same period in the previous year, the business posted ($76.00) earnings per share. Equities analysts anticipate that Editas Medicine, Inc. will post -2.71 EPS for the current fiscal year.
Editas Medicine Company Profile
(
Free Report)
Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
Read More
Before you consider Editas Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Editas Medicine wasn't on the list.
While Editas Medicine currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
